Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: Inoviorulez
Search This Board:
Last Post: 8/24/2016 6:55:22 PM - Followers: 138 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.


RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.


This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...


June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#3640  Sticky Note Rxi Pharmaceuticals (RXII) Research Report 2016 Inoviorulez 06/19/16 09:15:20 AM
#3884   Thank you for the free lecture in biotech The Other Guy 08/24/16 06:55:22 PM
#3883   RXI (and virtually all R&D biotechs), doesn't have sabaidii2 08/24/16 05:58:17 PM
#3882   The volume we saw in June was supposedly The Other Guy 08/24/16 05:48:41 PM
#3881   How big could this be if the FDA The Other Guy 08/24/16 05:46:04 PM
#3880   "Short Interest as of 8/15 dropped another 9,000 sabaidii2 08/24/16 05:31:46 PM
#3879   Short Interest as of 8/15 dropped another 9,000 The Other Guy 08/24/16 05:09:46 PM
#3878   The Dermatologist: Dermal Scarring Challenges Titan V 08/24/16 02:34:51 PM
#3877   Short interest is due to be disseminated after The Other Guy 08/24/16 09:48:42 AM
#3876   Before end of 2016 is what they stated Inoviorulez 08/16/16 06:17:39 PM
#3875   As of 6/30, all institutional ownership has been The Other Guy 08/16/16 09:36:15 AM
#3874   Geert from the CC: Titan V 08/15/16 09:31:54 PM
#3873   So when is the human trials starting for million_dollar_mafia 08/15/16 08:21:47 PM
#3872   have expressed an interest in talking to us The Other Guy 08/15/16 07:25:58 PM
#3871   You missed the Conference call then. The CEO Inoviorulez 08/15/16 06:36:32 PM
#3870   While I agree, RXi is reliant on sd-RNAi The Other Guy 08/15/16 11:26:24 AM
#3869   Thanks, I really hope RXi will not do BioPharma 08/15/16 09:19:20 AM
#3868   Not Necessarily. If you read the CC transcript Inoviorulez 08/14/16 10:13:52 PM
#3867   Question to this board about RXi financing issue. BioPharma 08/14/16 09:43:42 PM
#3866   Yes that's true but Cosmecueticals don't require FDA Inoviorulez 08/13/16 09:53:36 PM
#3865   "Scarring is blockbuster -- Global market for scars sabaidii2 08/13/16 09:48:38 PM
#3864   Scarring is blockbuster -- Global market for scars Inoviorulez 08/13/16 08:19:13 PM
#3863   "Which compound is RXi's blockbuster? I guess I sabaidii2 08/13/16 05:48:24 AM
#3862   I interpreted it to be 6 months from The Other Guy 08/12/16 04:03:44 PM
#3861   Yes obviously in vitro is not human testing. microchips 08/12/16 03:55:53 PM
#3860   microchips, "in vitro" is not human testing. The Other Guy 08/12/16 03:44:05 PM
#3859   Which compound is RXi's blockbuster? I guess The Other Guy 08/12/16 02:25:33 PM
#3858   Cosmeceuticals -------------- Human testing: duration is six months sabaidii2 08/12/16 02:08:50 PM
#3857   In the second quote he seems to be microchips 08/12/16 02:00:16 PM
#3856   But that doesn't align with this quote: The Other Guy 08/12/16 01:37:18 PM
#3855   The way I read it is 6 months microchips 08/12/16 01:34:04 PM
#3854   Is cosmeceuticals as far along in testing? The Other Guy 08/12/16 01:24:14 PM
#3853   Journal of Ocular Pharmacology and Therapeutics Titan V 08/12/16 11:13:23 AM
#3852   In due time?! Are you joking? Titan V 08/12/16 11:09:15 AM
#3851   I never rely on insider buying for investment The Other Guy 08/12/16 11:07:30 AM
#3850   "I think our frustrations will be rewarded in sabaidii2 08/12/16 11:00:45 AM
#3849   Proliferative Vitreoretinopathy (PVR) Therapeutics Development Pipeline Revie Titan V 08/12/16 10:32:02 AM
#3848   "If the company had $20 million in cash..." sabaidii2 08/12/16 10:29:53 AM
#3847   If the company had $20million in cash and The Other Guy 08/12/16 09:35:05 AM
#3846   RXI Pharmaceuticals' (RXII) CEO Geert Cauwenbergh on Q2 Titan V 08/12/16 12:04:08 AM
#3845   Recap of last set data from scar revision Titan V 08/11/16 11:48:48 PM
#3844   Living with Low Vision: Summary of Research and Titan V 08/11/16 10:28:51 PM
#3843   If the merger is w/ a bigger company, Titan V 08/11/16 07:19:23 PM
#3842   So he wants to merge with another company million_dollar_mafia 08/11/16 06:44:48 PM
#3841   They didn't talk about phase 3 if I'm Titan V 08/11/16 06:40:37 PM
#3840   He didn't but he did say they have Titan V 08/11/16 06:36:38 PM
#3839   What about how are they planning in funding million_dollar_mafia 08/11/16 06:33:39 PM
#3838   Did he say why a BO is not million_dollar_mafia 08/11/16 06:32:41 PM
#3837   Yes, BO not in the cards right now. Titan V 08/11/16 05:41:24 PM
#3836   Some good questions asked by the analysts on The Other Guy 08/11/16 05:32:00 PM
#3835   Judging by the lack of volume there is The Other Guy 08/11/16 03:54:18 PM